357 related articles for article (PubMed ID: 16034956)
1. Monoamine oxidase B inhibitors for early Parkinson's disease.
Macleod AD; Counsell CE; Ives N; Stowe R
Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD004898. PubMed ID: 16034956
[TBL] [Abstract][Full Text] [Related]
2. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
Caslake R; Macleod A; Ives N; Stowe R; Counsell C
Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
[TBL] [Abstract][Full Text] [Related]
4. Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial.
Gray R; Patel S; Ives N; Rick C; Woolley R; Muzerengi S; Gray A; Jenkinson C; McIntosh E; Wheatley K; Williams A; Clarke CE;
JAMA Neurol; 2022 Feb; 79(2):131-140. PubMed ID: 34962574
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis.
Binde CD; Tvete IF; Gåsemyr JI; Natvig B; Klemp M
Eur J Clin Pharmacol; 2020 Dec; 76(12):1731-1743. PubMed ID: 32710141
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of monoamine oxidase type B inhibitors plus channel blockers and monoamine oxidase type B inhibitors as adjuvant therapy to levodopa in the treatment of Parkinson's disease: a network meta-analysis of randomized controlled trials.
Yan R; Cai H; Cui Y; Su D; Cai G; Lin F; Feng T
Eur J Neurol; 2023 Apr; 30(4):1118-1134. PubMed ID: 36437702
[TBL] [Abstract][Full Text] [Related]
7. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
Binde CD; Tvete IF; Gåsemyr J; Natvig B; Klemp M
Br J Clin Pharmacol; 2018 Sep; 84(9):1917-1927. PubMed ID: 29847694
[TBL] [Abstract][Full Text] [Related]
8. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
[TBL] [Abstract][Full Text] [Related]
9. Dopamine agonist therapy in early Parkinson's disease.
Stowe RL; Ives NJ; Clarke C; van Hilten J; Ferreira J; Hawker RJ; Shah L; Wheatley K; Gray R
Cochrane Database Syst Rev; 2008 Apr; (2):CD006564. PubMed ID: 18425954
[TBL] [Abstract][Full Text] [Related]
10. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KD
Cochrane Database Syst Rev; 2001; 2001(1):CD001519. PubMed ID: 11279721
[TBL] [Abstract][Full Text] [Related]
11. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
Deane KH; Spieker S; Clarke CE
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118
[TBL] [Abstract][Full Text] [Related]
12. Cabergoline for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2001; 2001(1):CD001518. PubMed ID: 11279720
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
Talati R; Reinhart K; Baker W; White CM; Coleman CI
Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
[TBL] [Abstract][Full Text] [Related]
15. Ropinirole for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
[TBL] [Abstract][Full Text] [Related]
16. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
Lees A
Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
[TBL] [Abstract][Full Text] [Related]
17. Bromocriptine versus levodopa in early Parkinson's disease.
van Hilten JJ; Ramaker CC; Stowe R; Ives NJ
Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD002258. PubMed ID: 17943771
[TBL] [Abstract][Full Text] [Related]
18. Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease.
van Hilten JJ; Ramaker CC; Stowe R; Ives NJ
Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD003634. PubMed ID: 17943795
[TBL] [Abstract][Full Text] [Related]
19. Bromocriptine versus levodopa in early Parkinson's disease.
Ramaker C; van Hilten JJ
Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
[TBL] [Abstract][Full Text] [Related]
20. Ropinirole for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KH
Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
